{"nctId":"NCT00565266","briefTitle":"Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC)","startDateStruct":{"date":"2008-05"},"conditions":["Asthma"],"count":210,"armGroups":[{"label":"Tio + 1xICS || LABA + 1xICS || 2xICS","type":"EXPERIMENTAL","interventionNames":["Drug: tiotropium bromide","Drug: salmeterol xinafoate","Drug: beclomethasone dipropionate"]},{"label":"TIO + 1xICS || 2xICS || LABA + 1xICS","type":"EXPERIMENTAL","interventionNames":["Drug: tiotropium bromide","Drug: salmeterol xinafoate","Drug: beclomethasone dipropionate"]},{"label":"LABA + 1xICS || Tio + 1xICS || 2xICS","type":"EXPERIMENTAL","interventionNames":["Drug: tiotropium bromide","Drug: salmeterol xinafoate","Drug: beclomethasone dipropionate"]},{"label":"LABA + 1xICS || 2xICS || Tio + 1xICS","type":"EXPERIMENTAL","interventionNames":["Drug: tiotropium bromide","Drug: salmeterol xinafoate","Drug: beclomethasone dipropionate"]},{"label":"2xICS || Tio + 1xICS| || LABA + 1xICS","type":"EXPERIMENTAL","interventionNames":["Drug: tiotropium bromide","Drug: salmeterol xinafoate","Drug: beclomethasone dipropionate"]},{"label":"2xICS || LABA + 1xICS || Tio + 1xICS","type":"EXPERIMENTAL","interventionNames":["Drug: tiotropium bromide","Drug: salmeterol xinafoate","Drug: beclomethasone dipropionate"]}],"interventions":[{"name":"tiotropium bromide","otherNames":["SPIRIVA® HandiHaler®"]},{"name":"salmeterol xinafoate","otherNames":["Serevent® Diskus®"]},{"name":"beclomethasone dipropionate","otherNames":["QVAR® Inhalation Aerosol"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria for TALC and BASALT Studies:\n\n* Clinical history consistent with asthma\n* Forced expiratory volume in one second (FEV1) greater than 40% of predicted value\n* Asthma confirmed by one of the following two criteria:\n\n  1. Beta-agonist reversibility to 4 puffs albuterol of at least 12% OR\n  2. Methacholine provocative concentration at 20% (PC20) of 8 milligrams per milliliter (mg/mL) or less when not on an inhaled corticosteroid (ICS), or 16 mg/mL or less when on an ICS\n* Need for daily controller therapy (i.e., ICS, leukotriene modifiers, and/or long-acting beta-agonists) based on one or more of the following criteria:\n\n  1. Received prescription for or used asthma controller within the 12 months prior to study entry OR\n  2. Experienced symptoms for more than twice a week and not on asthma controller\n* If on inhaled steroids (any drug at any dose not exceeding the equivalent of 1000 micrograms (mcg) of fluticasone daily), participant must have been on a stable dose for at least 2 weeks prior to study entry\n* Non-smoker (i.e., total lifetime smoking history less than 10 pack-years; no smoking for at least 1 year prior to study entry)\n* Willing to use an effective form of birth control throughout the study\n\nInclusion Criteria for TALC Study:\n\n* Ability to measure morning (AM) peak expiratory flow (PEF) on schedule using electronic peak flow meter (EPFM) and to complete the study diary correctly at least 75% of the time during the interval between Weeks 2 and 4 of the run-in period\n* Adherence with study medication dosing at least 75% of the time during the interval between Weeks 2 and 4 of the run-in period\n* No asthma exacerbation requiring use of oral corticosteroids or additional asthma medications (including an increased dose of ICS) during the run-in period\n* FEV1 greater than 40% of the predicted value\n\nExclusion Criteria for BASALT and TALC Studies:\n\n* Lung disease other than asthma, including chronic obstructive pulmonary disease (COPD) and chronic bronchitis\n* Established or suspected diagnosis of vocal cord dysfunction\n* Significant medical illness other than asthma\n* History of respiratory tract infection within the 4 weeks prior to study entry\n* History of a significant asthma exacerbation within the 4 weeks prior to study entry\n* History of life-threatening asthma requiring treatment with intubation and mechanical ventilation in the 5 years prior to study entry\n* Hyposensitization therapy other than an established maintenance regimen\n* Inability to coordinate use of the delivery devices used in the study, based on the opinion of the investigator or clinical coordinator\n* Pregnant\n\nExclusion Criteria for TALC Study:\n\n* Inability to coordinate use of the medication delivery devices used in the study, based on the opinion of the investigator or clinical coordinator\n* Presence at Week 4 of the run-in period of any of the exclusion criteria stipulated for Week 0 of the run-in period (Note: Respiratory tract infections that do not cause the participant to meet exacerbation criteria are not considered exclusionary.)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change Between Week 14 and Week 0 in the Morning (AM) Peak Expiratory Flow (PEF)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.4","spread":"4.2"},{"groupId":"OG001","value":"18.0","spread":"3.2"},{"groupId":"OG002","value":"-1.4","spread":"3.5"}]}]}]},{"type":"SECONDARY","title":"Change Between Week 14 and Week 0 in the Forced Expiratory Volume in One Second (FEV1)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.12","spread":"0.025"},{"groupId":"OG001","value":"0.01","spread":"0.025"},{"groupId":"OG002","value":"0.02","spread":"0.025"}]}]}]},{"type":"SECONDARY","title":"Change Between Week 14 and Week 0 in Asthma Symptoms","description":"Asthma symptoms were recorded as 0 (absent = no symptom )\n\n1. (mild = symptom was minimally troublesome, i.e. not sufficient to interfere with normal daily activity or sleep)\n2. (moderate = symptom was sufficiently troublesome to interfere with normal daily activity or sleep)\n3. (severe = symptom was so severe as to prevent normal activity and/or sleep )","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.09","spread":"0.018"},{"groupId":"OG001","value":"-0.04","spread":"0.018"},{"groupId":"OG002","value":"0.03","spread":"0.018"}]}]}]},{"type":"SECONDARY","title":"Change Between Week 14 and Week 0 in the Asthma Quality-of-life Questionnaire Score","description":"Scores on the Asthma Quality-of-Life Questionnaire range from 1 to 7, with a higher score indicating a better quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.15","spread":"0.058"},{"groupId":"OG001","value":"0.28","spread":"0.050"},{"groupId":"OG002","value":"0.05","spread":"0.052"}]}]}]},{"type":"SECONDARY","title":"Change Between Week 14 and Week 0 in the Asthma Control Questionnaire Score","description":"Scores on the Asthma Control Questionnaire range from 0 to 6, with a higher score indicating worse asthma control.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.22","spread":"0.055"},{"groupId":"OG001","value":"-0.31","spread":"0.045"},{"groupId":"OG002","value":"-0.03","spread":"0.048"}]}]}]},{"type":"SECONDARY","title":"Change Between Week 14 and Week 0 in the Albuterol Rescue Puffs Per Day","description":"Total number of puffs from the albuterol (rescue) inhaler during the previous 24 hours (excluding those puffs for preventive use).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.11","spread":"0.058"},{"groupId":"OG001","value":"-0.16","spread":"0.063"},{"groupId":"OG002","value":"-0.07","spread":"0.063"}]}]}]},{"type":"SECONDARY","title":"Change Between Week 14 and Week 0 in the Proportion of Asthma Control Days","description":"An asthma control day was defined as a day in which there were no symptoms and no albuterol (rescue) puffs.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":"0.020"},{"groupId":"OG001","value":"0.14","spread":"0.023"},{"groupId":"OG002","value":"0.05","spread":"0.021"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":203},"commonTop":["urgent care visit due to asthma"]}}}